Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: "A. Sharma" Clear advanced filters

  • Imaging biomarkers (IBs) are used extensively in drug development and cancer research, but important differences exist between IBs and biospecimen-derived biomarkers. A tailored 'roadmap' is required for the development of new IBs to be used either in clinical research or for decision-making in healthcare. In this Consensus statement, a group of experts assembled by CRUK and the EORTC present 14 key recommendations for accelerating the clinical translation of IBs.

    • James P. B. O'Connor
    • Eric O. Aboagye
    • John C. Waterton
    ReviewsOpen Access
    Nature Reviews Clinical Oncology
    Volume: 14, P: 169-186

  • Can we exploit the DNA repair pathways in cancer cells to increase the efficacy of existing and future cancer treatments? This Review discusses the current state of play.

    • Thomas Helleday
    • Eva Petermann
    • Ricky A. Sharma
    Reviews
    Nature Reviews Cancer
    Volume: 8, P: 193-204

  • A multidisciplinary approach is essential for the optimization of patient care in oncology, especially in the current landscape, in which standard-of-care approaches to cancer treatment are evolving towards highly targeted treatments, precise image guidance and personalized cancer therapy. Herein, the authors discuss current career development pathways for oncologists, suggesting strategies to improve clinical training and research, with specific emphasis on the involvement of trainees in multidisciplinary teams.

    • Alison C. Tree
    • Victoria Harding
    • Ricky A. Sharma
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 14, P: 508-517

  • Interventional oncology aims to develop new disease-modifying treatment options beyond conventional surgical and oncological therapies. Clinical investigators should incorporate measures of cost-effectiveness and patient-reported outcomes into large-scale studies to provide robust evidence for changing clinical practice. In particular, interventional oncology trials could be designed to show that certain treatments might be as effective as the current standard of care, but with less morbidity and better outcomes for patients with cancer.

    • James M. Franklin
    • Val Gebski
    • Ricky A. Sharma
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 93-104